Company Filing History:
Years Active: 2019
Title: Christian Schroeter: Innovator in Anti-TNFα Antibodies
Introduction
Christian Schroeter is a notable inventor based in Darmstadt, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies that target tumor necrosis factor alpha (TNFα). His innovative work has the potential to improve therapeutic outcomes for patients suffering from various inflammatory diseases.
Latest Patents
Christian Schroeter holds a patent for "Anti-TNFα antibodies with pH-dependent antigen binding for improved target clearance." This invention relates to anti-TNFα antibodies that are engineered to exhibit pH-sensitive antigen binding. The patent is particularly focused on the anti-TNFα antibody adalimumab (Humira®) and its biologically active variants and fragments. The engineering involves modifications of the amino acid sequence within the variable regions, specifically altering the CDR domains by replacing one or more amino acid residues with histidine residues. This innovative approach aims to enhance the efficacy of the antibody in therapeutic applications.
Career Highlights
Christian Schroeter is currently associated with Merck Patent GmbH, where he continues to advance his research and development efforts. His work is characterized by a commitment to improving existing therapies and exploring new avenues in antibody engineering.
Collaborations
Christian has collaborated with esteemed colleagues such as Ralf Guenther and Stefan Becker. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to groundbreaking discoveries in the field.
Conclusion
Christian Schroeter's contributions to the development of pH-sensitive anti-TNFα antibodies exemplify the innovative spirit of modern biotechnology. His work not only advances scientific knowledge but also holds promise for improving patient care in inflammatory diseases.